The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on Saturday.
The new mid-stage trial will determine whether the vaccine is effective on people between the ages of 6 and 17, according to an emailed statement from the university.
Around 300 volunteers will be enrolled and first inoculations are expected this month, Oxford said.
The two-dose Oxford/AstraZeneca vaccine has been hailed as a "vaccine for the world" because it is cheaper and easier to distribute than some rivals.
AstraZeneca has a target to produce 3 billion doses this year and aims to produce over 200 million doses per month by April.
Sydney Airport flights disrupted due to air traffic controller shortage
Philippine firefighters enter charred ferry as search continues for dozens missing
More US lawmakers seek AI rules after Anthropic researchers warn of extinction
Fire in rebel-held east Congo kills 24 schoolchildren
Trump says he does not regret Iran war despite potential impact on elections
Trump touts $5,000 payout if Republicans win as Vance waits in wings
Search expands after Philippine ferry fire kills five and leaves dozens missing
Trump says Iran war to end after US midterm elections
